NP90323(c) Botulinum Toxin Type A Medicines (Xeomin®)
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Status | complete |
|---|---|
| Category (CPV) | 33600000 |
| Region | Scotland |
| Procedure | limited |
| OCID | ocds-h6vhtk-0407c5 |
Award
| Supplier | Value | Date | Status |
|---|---|---|---|
| Merz Pharma UK Ltd | · | · | active |
description
Supply of Botulinum Toxin Type A Medicines(Xeomin®) to NHS Scotland:
NP90323(c): Botulinum Toxin Type A Injection 50-unit vial/ Botulinum Toxin Type A Injection 100-unit vial/ Botulinum Toxin Type A Injection 200-unit vial (Xeomin®)
documents
- NP90323(c) Botulinum Toxin Type A Medicines (Xeomin®) , awardNotice
- NP90323(c) Botulinum Toxin Type A Medicines (Xeomin®) , awardNotice
Documents are linked, not mirrored. They are served by the publishing authority and may require registration.
notice history
2 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 4 Oct 2023 | Voluntary ex-ante transparency (F15) | Earlier regulations | 029230-2023 |
| 17 Nov 2023 | Contract award notice (F03) | Earlier regulations | 034029-2023 |
more from The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
- Insulin Infusion Pumps, Continuous Glucose Monitoring Systems and Associated Consumables · £140,000,000 · 9 Jul 2026
- Central Venous Catheters · £13,000,000 · 2 Jun 2026
- Sack Holders · £1,303,000 · 16 Apr 2026
- GP IT Systems · £1,500,000 · 1 Apr 2026
- TB Molecular · £467,800 · 1 Apr 2026
- Automated AST & Bacteria Testing · £6,192,812 · 27 Mar 2026
- NP884925 Adobe Licence · £53,937 · 27 Mar 2026
- Testing Service & Maintenance · £2,915,880 · 25 Mar 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Public Contracts Scotland. Contact details for named individuals are not reproduced on this site.